BACKGROUND & AIMS: Lack of detection technology for early pancreatic cancer invariably leads to a typical clinical presentation of incurable disease at initial diagnosis. New strategies and biomarkers for early detection are sorely needed. In this study, we have conducted a prospective sample collection and retrospective blinded validation to evaluate the performance and translational utilities of salivary transcriptomic biomarkers for the noninvasive detection of resectable pancreatic cancer. METHODS: The Affymetrix HG U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) was used to profile transcriptomes and discover altered gene expression in saliva supernatant. Biomarkers discovered from the microarray study were subjected to clinical validation using an independent sample set of 30 pancreatic cancer patients, 30 chronic pancreatitis patients, and 30 healthy controls. RESULTS: Twelve messenger RNA biomarkers were discovered and validated. The logistic regression model with the combination of 4 messenger RNA biomarkers (KRAS, MBD3L2, ACRV1, and DPM1) could differentiate pancreatic cancer patients from noncancer subjects (chronic pancreatitis and healthy control), yielding a receiver operating characteristic plot, area under the curve value of 0.971 with 90.0% sensitivity and 95.0% specificity. CONCLUSIONS: The salivary biomarkers possess discriminatory power for the detection of resectable pancreatic cancer, with high specificity and sensitivity. This report provides the proof of concept of salivary biomarkers for the noninvasive detection of a systemic cancer and paves the way for prediction model validation study followed by pivotal clinical validation. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: Lack of detection technology for early pancreatic cancer invariably leads to a typical clinical presentation of incurable disease at initial diagnosis. New strategies and biomarkers for early detection are sorely needed. In this study, we have conducted a prospective sample collection and retrospective blinded validation to evaluate the performance and translational utilities of salivary transcriptomic biomarkers for the noninvasive detection of resectable pancreatic cancer. METHODS: The Affymetrix HG U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) was used to profile transcriptomes and discover altered gene expression in saliva supernatant. Biomarkers discovered from the microarray study were subjected to clinical validation using an independent sample set of 30 pancreatic cancerpatients, 30 chronic pancreatitispatients, and 30 healthy controls. RESULTS: Twelve messenger RNA biomarkers were discovered and validated. The logistic regression model with the combination of 4 messenger RNA biomarkers (KRAS, MBD3L2, ACRV1, and DPM1) could differentiate pancreatic cancerpatients from noncancer subjects (chronic pancreatitis and healthy control), yielding a receiver operating characteristic plot, area under the curve value of 0.971 with 90.0% sensitivity and 95.0% specificity. CONCLUSIONS: The salivary biomarkers possess discriminatory power for the detection of resectable pancreatic cancer, with high specificity and sensitivity. This report provides the proof of concept of salivary biomarkers for the noninvasive detection of a systemic cancer and paves the way for prediction model validation study followed by pivotal clinical validation. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: B J Paster; S K Boches; J L Galvin; R E Ericson; C N Lau; V A Levanos; A Sahasrabudhe; F E Dewhirst Journal: J Bacteriol Date: 2001-06 Impact factor: 3.490
Authors: Lenora R Bigler; Charles F Streckfus; Lynn Copeland; Rebecca Burns; Xiaoli Dai; Melinda Kuhn; Patricia Martin; Steven A Bigler Journal: J Oral Pathol Med Date: 2002-08 Impact factor: 4.253
Authors: Marcia Irene Canto; Michael Goggins; Charles J Yeo; Constance Griffin; Jennifer E Axilbund; Kieran Brune; Syed Z Ali; Sanjay Jagannath; Gloria M Petersen; Elliot K Fishman; Steven Piantadosi; Francis M Giardiello; Ralph H Hruban Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: Jens Koopmann; Zhen Zhang; Nicole White; Jason Rosenzweig; Neal Fedarko; Sanjay Jagannath; Marcia I Canto; Charles J Yeo; Daniel W Chan; Michael Goggins Journal: Clin Cancer Res Date: 2004-02-01 Impact factor: 12.531
Authors: Lei Zhang; Hua Xiao; Hui Zhou; Silverio Santiago; Jay M Lee; Edward B Garon; Jieping Yang; Ole Brinkmann; Xinmin Yan; David Akin; David Chia; David Elashoff; No-Hee Park; David T W Wong Journal: Cell Mol Life Sci Date: 2012-06-12 Impact factor: 9.261
Authors: Janice M Yoshizawa; Christopher A Schafer; Jason J Schafer; James J Farrell; Bruce J Paster; David T W Wong Journal: Clin Microbiol Rev Date: 2013-10 Impact factor: 26.132
Authors: Martha E Arellano-Garcia; Roger Li; Xiaojun Liu; Yongming Xie; Xiaofei Yan; Joseph A Loo; Shen Hu Journal: Int J Mol Sci Date: 2010-09-02 Impact factor: 5.923